Blackstone’s Life Sciences group just added another sizable piece to its growing portfolio with the purchase of Japanese company Takeda Consumer Healthcare (TCHC) for $2.3 billion from its parent company.
The deal is being done via Oscar A-Co KK, a company that is controlled by Blackstone, which has rapidly grown its life sciences unit with a $4.6 billion asset raise for Blackstone Life Sciences V that was not only oversubscribed -- it was also the largest life . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Annual
$300
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
